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There has been a revolution in cancer treatment by target-based therapeutic development. Inhibition of genetic and 
epigenetic abnormalities via monoclonal antibodies and small-
molecule inhibitors have invigorated new hope in the treatment 
of cancer. The protein product of MET gene, hepatocyte growth 
factor (HGF) receptor, has been implicated in various onco-
genic processes, including cell proliferation, survival, invasion, 
motility, and metastasis. The human MNNG HOS transform-
ing gene (MET) located at 7q21-q31 was discovered in 1984 as 
a fusion partner with Tpr in the transforming fusion oncogene 
translocated promoter region-MET in immortalized osteosar-
coma cell line.1 MET precursor is post translationally digested 
and glycosylated, leading to formation of 50 kDa extracellular 
alpha-chain and transmembrane 140 kDa beta-chain.
Since its discovery, the MET/HGF pathway has been tar-
geted for cancer therapeutics. In the beginning, Dr. Catenacci 
discussed the general biology prognostic and predictive roles of 
MET amplification and expression in cancer. MET gene copy 
number (GCN) predicts expression in cell lines. High MET 
copy number and MET overexpression correlates with poor 
outcome in non–small-cell lung cancer (NSCLC) patients.2 
MET and KRAS gene amplification mediates acquired resis-
tance to MET tyrosine kinase inhibitors.3 A drug-resistance 
screen using a selective MET inhibitor revealed a spectrum of 
mutations that partially overlap with activating mutations found 
in cancer patients.4 Recently we described a durable complete 
response obtained with a molecularly- targeted monoclonal 
antibody, MetMAb, to the receptor tyrosine kinase, MET, 
in a patient with chemorefractory metastatic gastric cancer.5 
Understanding the biology of MET/HGF pathway will lead to 
better therapeutics against cancer, especially thoracic malig-
nancies. Ultimately, we need to be able to understand the 
mechanisms of resistance so that they can be overcome.
METMAB (ONARTUZUMAB)
Dr. David R. Spigel discussed MetMAb, a single-armed 
monovalent, humanized modified 5D5 anti-MET antibody, 
specifically designed to avoid agonistic activity that may 
occur when a bivalent antibody binds two MET molecules.6 
MetMAb binds to the Sema domain of MET, an extracel-
lular region essential for binding its ligand, HGF, inhibiting 
HGF from binding to MET, thereby blocking ligand-induced 
MET dimerization and activation of the intracellular kinase 
domain,7 leading to inhibition of the downstream signaling 
activity and cellular response.8 Phase Ia/Ib dose-escalation 
study with MetMAb as single agent (34 patients) and in com-
bination with bevacizumab (nine patients) established the 
safety and recommended dose of 15 mg/kg every 3 weeks. One 
patient with gastric cancer in the only cohort with MetMAb 
showed complete response after four cycles of treatment.9 
Profile suggested an autocrine pathway with absence of focal 
MET amplification, MET mutation, and substantial decrease 
in pretreatment levels of elevated serum HGF with MetMAb 
treatment. In a global, randomized, double-blind phase II 
study, comparing MetMAb plus erlotinib (ME) to placebo 
plus erlotinib (PE) in second-/third-line NSCLC, 128 patients 
were randomized between two arms with 95%, 88%, and 75% 
tissue available from c-Met immunohistochemistry (IHC), 
EGFR/KRAS mutations and MET fluorescence in situ hybrid-
ization (FISH) analysis, respectively. Coprimary objectives 
were progression-free survival (PFS) in Met-diagnostic posi-
tive (Dx+) patients and intention to treat population. In Met 
Dx+ NSCLC, which constituted more than half the population 
(54%), ME resulted in clinically and statistically improved 
PFS and overall survival (OS), with OS benefit noted both 
in MET FISH of 5 copies+ or more (as well as FISH−/IHC 
2+/3+ (n = 65, hazard ratio [HR] =0.37, median 12.6 months 
versus 4.6 months, p = 0.002) patients. This benefit was not 
exclusive to EGFR mutant or MET FISH+ alone (p = 0.19) 
and was observed in FISH−/IHC+ (p = 0.09), signifying that 
IHC might be a more sensitive MetMAb response predictor.10 
There are ongoing phase II trials on NSCLC, colorectal can-
cer, and glioblastoma multiforme. A phase III trial of Erlotinib 
(E) +/− MetMAb (M) in second- and third-line NSCLC is cur-
rently underway, looking at OS as primary endpoint.
TIVANTINIB
Dr. Alan Sandler presented tivantinib, an oral, non-
adenosine triphosphate dependent, selective MET inhibitor. 
Tivantinib inhibits MET autophosphorylation and is highly 
selective for the inactive or unphosphorylated form of MET.11
Data from a global randomized placebo-controlled 
phase II clinical trial of erlotinib (E) plus tivantinib (T) ver-
sus erlotinib (E) plus placebo (P) in previously treated EGFR 
inhibitor-naive patients, with locally advanced or metastatic 
NSCLC, were presented. One hundred and sixty-seven 
patients were randomized to E+A (84 patients) or E+P (83 
patients) with some imbalance in treatment arms in NSCLC 
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histology (56% –65% adenocarcinoma) and predictive molec-
ular genotypes: EGFR mutations (11%–19%) and KRAS 
mutations (17%–10%). Median PFS was 3.8 months for 
ET and 2.3 months for EP (HR = 0.81; 95% CI, 0.57–1.16; 
p= 0.24). Exploratory analysis revealed that the small cohort 
with KRAS mutations achieved a PFS HR of 0.18 (95% 
CI, 0.05–0.70;interaction p = 0.006). PFS benefit was also 
noted for tumors harboring amplified c-Met, wild-type (wt) 
EGFR, and nonsquamous histology.12 Phase III (Met inhibitor 
ARQ 197 plus Erlotinib vs Erlotinib plus placebo in NSCLC 
[MARQUEE]) trial is underway where inoperable, locally 
advanced, or metastatic nonsquamous histology NSCLC with 
EGFR-TKI–naive (1–2 regimens of prior chemotherapy) are 
randomized between erlotinib (E) 150 mg daily plus tivantinib 
(T) 360 mg twice daily versus erlotinib (E) plus placebo (P). 
Primary endpoint is OS in ITT population. Secondary end-
points are PFS, pharmacokinetics, pharmacodynamics analy-
sis, OS, and PFS in EGFR wt patients, safety, toxicity, and 
Quality of life. This study has nearly completed its accrual at 
the time of writing this article.
LY2801653
Dr. Richard Gaynor presented data regarding 
LY2801653, an orally bioavailable, selective, reversible, type-
II adenosine triphosphate competitive inhibitor of MET, capa-
ble of inhibiting both ligand-dependent and/or independent 
phosphorylation of MET. This drug was designed to inhibit 
the closely related growth factor receptor recepteur d’Origine 
Nantais (RON), with cell-based half maximal inhibitory con-
centration of 0.0111 μM for macrophage stimulating protein 
induced phosphorylation. Xenograft model showed tumor vol-
ume reduction of 92% with 12/mg/kg oral dosing. LY2801653 
reduced tumor growth/metastasis and enhanced survival of 
mice bearing orthotopic NSCLC tumors. LY2801653 has 
potent antitumor efficacy in a number of non–small-cell lung, 
renal, pancreatic, and breast tumor models. MET expression 
in these tumors by IHC exposed correlation between response 
and MET expression. The two non–small--cell lung adeno-
carcinoma models LXFA526 and LXFA1647 that were resis-
tant to EGFR inhibitors Cetuximab and Erlotinib, displayed 
high sensitivity toward LY2801653.13 There is an ongoing 
phase I study (I3O-MC-JSBA) of LY2801653 in patients with 
advanced cancer, with primary endpoint being recommended 
dose for phase II studies (NCT01285037).
CRIZOTINIB
Dr. Ignatius Ou presented data regarding A8081002 
trial. A8081002 (NCT00965731) is a combination study of 
erlotinib in combination with crizotinib in NSCLC, with the 
intention of randomizing NSCLC patients to erlotinib ± crizo-
tinib in advanced NSCLC, once the recommended phase II 
dose level of the erlotinib–crizotinib combination is achieved. 
Crizotinib 150 mg twice daily + Erlotinib100 mg once daily is 
the maximum tolerable combination. Crizotinib 150 mg twice 
daily or 200 mg twice daily increased Erlotinib area under 
the curve by 1.5 to 1.7 fold. Plasma exposure to erlotinib of 
100 mg once daily was equivalent to that of 150 mg once daily 
when dosing with either 200 mg twice daily or 150 mg twice 
daily crizotinib. Dr. Ou and colleagues14 previously described 
an NSCLC patient with MET amplification and anaplastic 
lymphoma kinase wt that responded to Crizotinib.
FORETINIB
Dr. Glen Goss reviewed foretinib, a small-molecule 
kinase inhibitor that targets members of the HGF and vas-
cular endothelial growth factor receptor tyrosine kinase 
families (dual VEGFR2/MET inhibitor). It has inhibitory 
activity toward FMS-like tyrosine kinase (Flt-3), v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), 
platelet-derived growth factor receptor (PDGFR-β), and tyro-
sine kinase with immunoglobulin-like and EGF-like domains 
(Tie-2) only at appreciably higher concentrations, and there-
fore is not a potent inhibitor of these receptors. In NSCLC 
cell lines with coactivation of EGFR and MET with foretinib 
and erlotinib in combination results in synergistic inhibi-
tion.15 In a phase II study of foretinib in papillary renal cell 
carcinoma, high incidence of hypertension (81%) was noted 
with over 50% being grade 3/4. In hepatocellular carcinoma, 
up-regulation of Met-signaling and circulating levels of HGF 
correlate with prognosis. A phase I/II study in Asian patients 
with hepatocellular carcinoma, established maximum toler-
ated dose (MTD) of 30 mg. Phase II study is ongoing. There is 
currently a randomized, multicenter phase I/II trial, sponsored 
by NCIC-CTG, with phase I end points being MTD, safety, 
tolerability, and pharmacokinetic profile. Phase II would ran-
domize patients (N = 80) between erlotinib and foretinib ver-
sus erlotinib alone, and will be looking at the overall response 
rate, tumor size at 8 weeks, 1-year OS, and PFS.
CABOZANTINIB
Dr. Heather Wakelee discussed cabozantinib, a potent 
inhibitor of MET and VEGFR2, which also inhibits rear-
ranged during transfection (RET), KIT, anexelekto, and 
FLT3.16 A phase I (3+3 design), two-arm study was under-
taken with one arm to maximize erlotinib and the other arm 
to maximize cabozantinib dose. Fifty-four pretreated NSCLC 
patients were enrolled (52 with prior erlotinib)–Cabozantinib 
50 (40) mg plus erlotinib 150 mg was MTD of arm 2, and 
Cabozantinib 125 (100) mg plus erlotinib 50 mg was the 
MTD for arm 1. Encouraging clinical activity has been seen 
in a largely erlotinib-pretreated population, including patients 
with EGFRT790M. A phase II study of Cabozantinib 100 mg 
plus erlotinib 50 mg versus Cabozantinib 100 mg single agent 
opened in acquired resistance patients. Accrual was halted at 
30 patients. No results have yet been reported. Cabozantinib 
recently became available through Cancer Therapy Evaluation 
Program for potential trials. It would also be important to 
determine the effectiveness of cabozantinib for patients with 
RET translocations.
RILOTUMUMAB
Dr. Mark Socinski discussed rilotumumab, a humanized 
monoclonal antibody directed against HGF, which interferes 
with the interaction between HGF and MET, preventing MET 
activation.17 Rilotumumab enhances efficacy of temozolomide 
and docetaxel in U-87 MG cells and xenograft models.18 There 
S374 Copyright © 2012 by the International Association for the Study of Lung Cancer
Santa Monica Supplement Journal of Thoracic Oncology  •  Volume 7, Number 12, Supplement 5, December 2012
are three ongoing phase II nonthoracic malignancy trials, 
including gastric, colon, and prostate. Elevated serum HGF 
correlates with gastric cancer stage, with resection leading to 
a drop in levels. Met is frequently overexpressed in gastric 
cancer (40%–65%). Phase II study (Amgen Trial 20060317; 
ClinicalTrials.gov identifier NCT00719550) evaluating 
Rilotumumab (R) with epirubicin, cisplatin, and capecitabine 
(ECX). Median PFS with (R+ECX) was 5.6 months com-
pared with 4.2 months for placebo (P) plus ECX. Median OS 
was 11.1 months versus 8.9 months. PFS and OS in METhigh 
patients were 6.9 months versus 4.6 months and 11.1 months 
versus 5.7 months. R+ECX showed all grade neutropenia 
(54%), peripheral edema (27%), and alopecia (41%) had a 
point difference of 15% or more compared with (P+ECX). 
There are three ongoing clinical trials in thoracic malignan-
cies, including small–cell lung cancer (NCT00791154), meso-
thelioma (NCT01105390), and NSCLC (NCT01233687).
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